Vaccines for a potential influenza pandemic

Future Microbiology

Volumn 2, Issue 3, 2007, Pages 345-349

  Auewarakul, Prasert ^a   Thongcharoen, Prasert ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Pandemic influenza; Review; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; HEMAGGLUTININ; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; SPLIT VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS VACCINE;

CLINICAL TRIAL; CROSS REACTION; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS A H5N1; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SEROCONVERSION; SINGLE DRUG DOSE; VIRUS STRAIN;

ANIMALS; BIRDS; CLINICAL TRIALS AS TOPIC; DISEASE OUTBREAKS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA VACCINES; INFLUENZA, HUMAN;

AVES;

EID: 34547514505     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460913.2.3.345     Document Type: Review

References (19)

1. Ferguson NM, Cummings DA, Fraser C et al.: Strategies for mitigating an influenza pandemic. Nature 442, 448-452 (2006).
2. Bardiya N, Bae JH.: Influenza vaccines: recent advances in production technologies. Appl. Microbiol. Biotechnol. 67, 299-305 (2005).
3. Kieny MP, Costa A, Hombach J et al.: A global pandemic influenza vaccine action plan. Vaccine 24, 6367-6370 (2006).
4. Robertson JS, Nicolson C, Newman R et al.: High growth reassortant inluenza vaccine viruses: new approaches to their control. Biologicals 20, 213-220 (1992).
5. Gerdil C: The annual production cycle for influenza vaccine. Vaccine 21, 1776-1779 (2003).
6. Eckert EA: Alkaline-extracted influenza subunit vaccine. Infect. Immun. 14, 1302-1308 (1876).
7. Webster RG, Govorkova EA: H5N1 Influenza - continuing evolution and spread. N. Engl. J. Med. 355, 2174-2177 (2006).
8. World Health Organization Global Influenza Program Surveillance Network: Evolution of H5N1 avian influenza viruses in Asia. Emerg. Infect. Dis. 11, 1515-1521 (2005).
9. Chen H, Smith GJ, Li KS et al.: Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proc Natl Acad Sci USA 103, 2845-2850 (2006).
10. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M: Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Ergl. J. Med. 354, 1343-1351 (2006).
11. Stephenson I, Bugarini R, Nicholson KG et al.: Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy, J. Infect. Dis. 191, 1210-1215 (2005).
12. Bresson JL, Perronne C, Launay O et al.: Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: Phase I randomised trial. Lancet 367, 1657-1664 (2006).
13. Lin J, Zhang J, Dong X et al.: Safety and Imunogenicity of an inactivated adjuvanted whole-viron infleunza A (H5N1) vaccine: a Phase I randomized controlled trial. Lancet 368, 991-997 (2006).
14. Bernstein DI, Zahradnik JM, DeAngelis CJ, Cherry JD: Clinical reactions and serologic responses after vaccination with whole-virus or split-virus influenza vaccines in children aged 6 to 36 months. Padiatrics 69, 404-408 (1982).
15. Mabrouk T, Ellis RW: Influenza vaccine technologies and the use of the cell-culture process (cell-culture influenza vaccine). Dev Biol. (Based) 110, 125-134 (2002)
16. Pau MG, Ophorst C, Koldijk MH et al.: The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 19, 2716-2721 (2001).
17. Treanor JJ, Schiff GM, Couch RB et al.: Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J. Infect. Dis. 193, 1223-1228 (2006).
18. Harper SA, Fukuda K, Cox NJ, Bridges CB: Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Racomm. Rep. 52. 1-8 (2003).
19. Suguitan AL Jr, McAuliffe J, Mills KL et al.: Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS. Med. 3, e360 (2006).